Our hollow-fiber infection model simulated the projected steady-state pharmacokinetics of ceftolozane and tazobactam in lung epithelial lining fluid of patients with pneumonia receiving 3 g of ceftolozane/tazobactam every 8 hours. Results confirmed the previously established in vitro activity of ceftolozane/tazobactam at and above approved breakpoints against multidrug-resistant Pseudomonas aeruginosa, regardless of Pseudomonas-derived cephalosporinase allele.
Keywords: Pseudomonas aeruginosa; antibacterial resistance; hollow-fiber infection model; pharmacokinetics/pharmacodynamics.
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.